Picture of Cytosorbents logo

CTSO Cytosorbents Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-4.49%
3m-19.51%
6m-66.75%
1yr-76.55%
Volume Change (%)
10d/3m-68.17%
Price vs... (%)
52w High-76.46%
50d MA-14.09%
200d MA-54.12%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-83.59%
Return on Equity-104.07%
Operating Margin-80.15%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Cytosorbents EPS forecast chart

Profile Summary

CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its polymer adsorption technology. Its lead product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy, and pancreatitis. Its other products include CytoSorb, animal-targeted VetResQ, DrugSorb-ATR, ECOS-300CY. Its other product candidates under development, including CytoSorb XL, BetaSorb, ContrastSorb, DrugSorb, HemoDefend-RBC, HemoDefend-BGA, K+ontrol, and others consist of a cartridge containing adsorbent, porous polymer beads, although the polymers used in these devices are physically different.

Directors

Last Annual
December 31st, 2022
Last Interim
September 30th, 2023
Incorporated
October 28th, 2014
Public Since
June 17th, 2005
No. of Shareholders
11,200
No. of Employees
198
Sector
Healthcare Equipment & Supplies
Industry
Healthcare
Exchange
us flag iconNASDAQ Capital Market
Shares in Issue
52,211,599

CTSO Share Price Performance

Upcoming Events for CTSO

Cytosorbents Corp at TD Cowen Health Care Conference

Q4 2023 Cytosorbents Corp Earnings Release

Q1 2024 Cytosorbents Corp Earnings Release

Cytosorbents Corp Annual Shareholders Meeting

Q2 2024 Cytosorbents Corp Earnings Release

Similar to CTSO

Picture of Accelerate Diagnostics logo

Accelerate Diagnostics

us flag iconNASDAQ Capital Market

Picture of Acutus Medical logo

Acutus Medical

us flag iconNASDAQ Capital Market

Picture of Adapthealth logo

Adapthealth

us flag iconNASDAQ Capital Market

Picture of Aethlon Medical logo

Aethlon Medical

us flag iconNASDAQ Capital Market

Picture of Agape ATP logo

Agape ATP

us flag iconNASDAQ Capital Market

FAQ